Metabolism, Inborn Errors: Clinical Trials

3,440 trials for Metabolism, Inborn Errors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1846 completed, 481 recruiting, 389 unknown, 220 terminated. 716 Phase 2, 575 Not applicable, 535 Phase 1, 450 Phase 3, 176 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2716Completed 420, Terminated 77, Recruiting 62, Active not recruiting 46, Unknown 39, Withdrawn 33, Not yet recruiting 22, Enrolling by invitation 11, Suspended 6
Not applicable575Completed 324, Unknown 92, Recruiting 68, Not yet recruiting 31, Active not recruiting 23, Terminated 18, Withdrawn 11, Enrolling by invitation 7, Suspended 1
Phase 1535Completed 328, Recruiting 61, Terminated 49, Active not recruiting 35, Unknown 18, Withdrawn 18, Not yet recruiting 17, Enrolling by invitation 5, Suspended 4
Phase 3450Completed 301, Active not recruiting 34, Recruiting 33, Terminated 32, Unknown 21, Withdrawn 13, Not yet recruiting 10, Enrolling by invitation 6
Phase 4176Completed 105, Recruiting 21, Unknown 19, Terminated 13, Withdrawn 9, Active not recruiting 4, Not yet recruiting 4, Enrolling by invitation 1
Early Phase 141Completed 15, Recruiting 9, Unknown 6, Terminated 5, Active not recruiting 3, Not yet recruiting 3

Follow Metabolism, Inborn Errors: new trials by email Literature Review of Metabolism, Inborn Errors trials Research Report on Metabolism, Inborn Errors

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria
GS1168 injection - Phenylketonuria (PKU)
Early Phase 1Not yet recruitingGritgen Therapeutics Co., Ltd.92027-12-312026-09-10
IT and IV Lentiviral Gene Therapy for X-ALD
Intrathecal and intravenous LV gene therapy - X-linked Adrenoleukodystrophy
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute302027-06-012026-11-02
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD
Lentiviral TYF-ARSA correction of patient's autologous HSCs - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-06-012026-11-02
Direct Lentiviral Injection Gene Therapy for MLD
Intrathecal and intravenous LV gene therapy - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-05-312026-11-02
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Phase 1 / Phase 2Not yet recruitingGeorge Washington University242027-03-012026-10-05
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
garetosmab - Fibrodysplasia Ossificans Progressiva, FOP
Phase 3Not yet recruitingRegeneron Pharmaceuticals182027-02-022026-11-12
A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion
Gaucher Disease
Not yet recruitingTakeda602027-01-312026-10-01
Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)
AZ-3102 - Gaucher Disease Type 3
Phase 2Not yet recruitingAzafaros B.V.202027-01-252026-11-12
Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB
rAAV9-CMV-hNAGLUop - Sanfilippo Syndrome (MPS III)
Phase 1 / Phase 2Not yet recruitingNeuroGT92027-01-182026-09-14
Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical Trial
Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase - GM1 Gangliosidoses, GM1 Gangliosidosis, Type I
Phase 1Not yet recruitingTippi Mackenzie52027-01-012026-08-31
Outside the Cage (OTC) Robotic Esophagectomy
OTC MIE Esophagectomy - Esophageal Cancer
Phase 1Not yet recruitingCentre hospitalier de l'Université de Montréal (CHUM)312027-01-012026-03-18
Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia
exposure to healthcare transition protocol - Congenital Adrenal Hyperplasia
Not yet recruitingUniversity of Alabama at Birmingham402027-01-012026-10-14
European Cystinosis Cohort 2
Cystinosis
Not yet recruitingInstitut National de la Santé Et de la Recherche Médicale, France2502027-01-012026-11-03
An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia
Hypercholesterolaemia, Familial Hypercholesterolaemia
Not yet recruitingFondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)25002027-01-012026-11-03
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
GD2, PSMA and CD276 CAR-T cells - Neuroblastoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002026-12-312026-10-30
The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)
Venglustat, Imiglucerase - Gaucher's Disease Type III
Phase 3Not yet recruitingSanofi182026-12-112026-11-10
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
AZ-3102 - Niemann-Pick Disease Type C, GM2 Gangliosidosis
Phase 2 / Phase 3Not yet recruitingAzafaros B.V.2182026-12-102026-10-21
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)
PLX-200 - Lysosomal Storage Disorders, Sandhoff Disease
Phase 2Not yet recruitingPolaryx Therapeutics, Inc.242026-12-012026-07-31
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)
NBIP-01435 - Congenital Adrenal Hyperplasia
Phase 2Not yet recruitingNeurocrine Biosciences362026-12-012026-09-30
Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)
Tralesinidase alfa (TA) - MPS IIIB
Phase 3Not yet recruitingSpruce Biosciences142026-12-012026-09-21

Showing 20 of 3440. Sign in to see all of them.

Narrower conditions

Gout (309)  ·  Fabry Disease (243)  ·  Hyperlipoproteinemia Type II (227)  ·  Phenylketonurias (189)  ·  Amyloid Neuropathies, Familial (186)  ·  Gaucher Disease (176)  ·  Glycogen Storage Disease Type II (147)  ·  Lysosomal Storage Diseases (123)  ·  Mucopolysaccharidosis IV (101)  ·  Adrenal Hyperplasia, Congenital (100)  ·  Hyperuricemia (98)  ·  Rare Diseases (94)  ·  Genetic Diseases, Inborn (93)  ·  Metabolic Diseases (93)

Broader conditions

Nutritional and Metabolic Diseases (3434)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3433)  ·  Genetic Diseases, Inborn (3347)  ·  Metabolic Diseases (3346)  ·  Nervous System Diseases (1666)  ·  Central Nervous System Diseases (1342)  ·  Brain Diseases (1336)  ·  Brain Diseases, Metabolic (1274)  ·  Brain Diseases, Metabolic, Inborn (1269)  ·  Lipid Metabolism Disorders (1108)  ·  Lipid Metabolism, Inborn Errors (1091)  ·  Lysosomal Storage Diseases (959)  ·  Carbohydrate Metabolism, Inborn Errors (731)  ·  Lysosomal Storage Diseases, Nervous System (709)

Interventions

Febuxostat (46)  ·  Allopurinol (45)  ·  Ganciclovir (44)  ·  sapropterin (37)  ·  GAA protein, human (36)  ·  Blood Specimen Collection (32)  ·  Colchicine (31)  ·  agalsidase beta (28)  ·  migalastat (28)  ·  agalsidase alfa (24)  ·  Ezetimibe (20)  ·  burosumab (20)  ·  larazotide acetate (19)  ·  Iduronidase (18)  ·  miglustat (18)

Sponsors

Genzyme, a Sanofi Company (79)  ·  BioMarin Pharmaceutical (60)  ·  Shire (55)  ·  Alexion Pharmaceuticals, Inc. (51)  ·  Assistance Publique - Hôpitaux de Paris (44)  ·  Amicus Therapeutics (38)  ·  CENTOGENE GmbH Rostock (34)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (34)  ·  Novartis Pharmaceuticals (34)  ·  National Center for Research Resources (NCRR) (33)  ·  Takeda (31)  ·  Amgen (29)  ·  Sanofi (29)  ·  Pfizer (28)  ·  National Human Genome Research Institute (NHGRI) (27)

Countries

United States (1579)  ·  France (475)  ·  United Kingdom (471)  ·  Germany (365)  ·  Canada (338)  ·  Italy (298)  ·  Spain (257)  ·  Netherlands (214)  ·  China (192)  ·  Australia (184)  ·  Brazil (154)  ·  Belgium (130)  ·  Denmark (124)  ·  Turkey (Türkiye) (121)  ·  Taiwan (112)

Top investigators

Peter Bauer, Prof. (20)  ·  Forbes D Porter, M.D. (12)  ·  Ozlem Goker-Alpan, MD (10)  ·  Paul Orchard, MD (10)  ·  Anita MacDonald (8)

Results publications

PMID 33874971, PMID 39151033, PMID 27657681, PMID 19775921, PMID 24144944, PMID 26529632, PMID 33990512, PMID 35835008, PMID 37624739, PMID 40601241, PMID 21353107, PMID 21586746, PMID 22052584, PMID 22961727, PMID 24122883, PMID 25803389, PMID 27578134, PMID 27839979, PMID 30467742, PMID 32417537, PMID 32593547, PMID 32721016, PMID 32762706, PMID 33332761, PMID 33527139, PMID 34617591, PMID 35709957, PMID 36279795, PMID 36520008, PMID 37415957, PMID 39383458, PMID 39847314, PMID 40193200, PMID 40411344, PMID 40525490, PMID 40587053, PMID 40962182, PMID 41388232, PMID 41631150, PMID 42389794, PMID 16911575, PMID 17407645, PMID 18473686, PMID 18600509, PMID 19029469, PMID 20188616, PMID 20393176, PMID 21401833, PMID 21613319, PMID 21637107

NIH funding

2023 (24), 2018 (20), 2015 (19), U54NS065768 (19), 2019 (18), 2014 (14), 2016 (14), 2017 (13), 2025 (13), 2008 (8), 2009 (7), 2005 (6), U54DK083908 (4), U54NS078059 (4), U54HD061221 (3)